SGOV vs XBI
iShares 0-3 Month Treasury Bond ETF vs SPDR S&P Biotech ETF
SGOV$100.45
iShares 0-3 Month Treasury Bond ETF
0-3 month T-bills, low-duration cash alternative.
Expense: 0.09%Yield: 3.94%
XBI$133.66
SPDR S&P Biotech ETF
Equal-weight biotech stocks in the S&P Biotech Index.
Expense: 0.35%Yield: 0.34%
Quick take
- • SGOV has the lower expense ratio at 0.09% vs 0.35% for XBI.
- • SGOV pays a higher dividend yield (3.94%).
Side-by-side metrics
| Metric | SGOV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.09% | 0.35% |
Dividend yield Trailing 12-month yield. | 3.94% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $85.15B | $8.30B |
YTD return | 1.23% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.00 | 1.09 |
P/E ratio | — | — |
Last price | $100.45 | $133.66 |
Inception | — | — |
Issuer | iShares | State Street |
SGOV top holdings
Holdings data unavailable for SGOV.
XBI top holdings
Top holdings · XBI
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
Sector breakdown · XBI
Financial Services0.2%
Healthcare99.8%
About SGOV
SGOV (iShares 0-3 Month Treasury Bond ETF) is 0-3 month T-bills, low-duration cash alternative. Managed by iShares, the fund carries $85.2B in assets under management, an expense ratio of 0.09%, a dividend yield of 3.94%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.